These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2011-004651-40 A multi-center, open label, uncontrolled, Phase IIa clinical trial evaluating the safety and efficacy of NOX-A12 in combination with a background therapy of bortezomib and dexamethasone (VD) in previo... 2015-09-30 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-004672-11 A multi-centre, open label, uncontrolled, Phase IIa clinical trial evaluating the safety and efficacy of NOX-A12 in combination with a background therapy of bendamustine and rituximab (BR) in previous... 2017-04-27 bad-data
Reported results 2011-005710-11 A phase IIa study to characterize the effects of CCL2 inhibition with the SpiegelmerĀ® NOX-E36 in patients with type 2 diabetes mellitus and albuminuria. 2013-12-03 due-trials
Reported results 2012-001525-27 Phase IIa study to characterize the effects of the SpiegelmerĀ® NOX H94 on anemia of chronic disease in patients with cancer 2013-12-30 due-trials
Reported results 2013-003585-14 Safety, PK/PD and efficacy of NOX-H94 in dialysis patients with ESA-hyporesponsive anaemia: A randomized, double blind, placebo controlled parallel group study with a single blind cross-over group 2015-11-16 due-trials
Exempt 2016-003657-15 A Two-Part, Open-Label Phase 1/2 Study to Evaluate Pharmacodynamic Effects and Safety of Olaptesed Pegol Monotherapy and Safety and Efficacy of Olaptesed Pegol / Pembrolizumab Combination Therapy in M... not-yet-due